Blog

Blog

By Dr. Mark Roskey and Dr. David Duffy

We were honored to be able to speak about the promise of immuno-oncology (IO) therapeutics at this year’s Molecular Med Tri-Con conference and the 12th Annual Biomarkers Congress. Bringing together thought leaders from around the world, including academics, pharma customers and therapeutic companies, these conferences are critical for the acceleration of precision health for improved treatment methods across a variety of disease-types.